Skip to content

Evidence-based study on the correlation between type 2 diabetes and cardiovascular disease

Evidence-based study on the correlation between type 2 diabetes and cardiovascular disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2200006065
Enrollment
Unknown
Registered
2022-06-05
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus and cardiovascular disease

Interventions

???:no

Sponsors

The First Affiliated Hospital of Guangdong Pharmaceutical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Research topics (1), type 2 diabetes and the impact of TCM differences on the short-term and long-term prognosis of secondary ACS in patients with SCAD Inclusion criteria: ? age = 18 years; ? the first diagnosis in line with stable coronary heart disease patients; ? in line with the syndrome differentiation criteria of TCM; ? outpatient follow-up time = 12 months; ? voluntary participation in this study and signed informed consent. Research subjects (2), ACS patients with new diabetes after PCI risk factor analysis and integrated traditional Chinese and western medicine risk prediction model establishment inclusion criteria: ? age = 18 years; ? the first diagnosis in line with acute coronary syndrome (including unstable angina, acute myocardial infarction); ? in line with the diagnostic criteria of blood stasis syndrome in traditional Chinese medicine; ? accept the first coronary stent implantation; ? outpatient follow-up time = 12 months; ? voluntary participation in this study.

Exclusion criteria

Exclusion criteria: Study subjects (1) The impact of type 2 diabetes and TCM differences on the short-term and long-term prognosis of secondary ACS in patients with SCAD Exclusion criteria: (1) Patients who have undergone cardiac bypass; (2) Patients with severe liver and kidney dysfunction; (3) Patients with severe heart disease other than coronary artery disease, menstrual disease, cancer, pregnancy, perioperative hemodynamic instability; (4) Patients with acute metabolic disorders such as diabetic ketoacidosis and serious complications such as infection in the past 1 month; (5) Patients participating in other clinical trials. Research subjects (2) ACS patients with new diabetes after PCI risk factor analysis and integrated traditional Chinese and western medicine risk prediction model establishment exclusion criteria: (1) patients who have undergone cardiac bypass; (2) PCI treatment before the history of diabetes, hypoglycemic agents (or insulin) medication history, fasting blood glucose greater than 7.0 mmol/l, glycosylated hemoglobin = 6.5%; (3) with severe liver and kidney dysfunction; (4) with Alzheimer's disease, mental illness or depression; (5) after PCI did not take coronary heart disease secondary drugs; (6) participate in clinical trials.

Design outcomes

Primary

MeasureTime frame
LDL cholesterol;cholesterol;Glycosylated hemoglobin;Fasting plasma glucose;triglycerides;

Countries

CHINA

Contacts

Public ContactGuo Jiao
guoj@gdpu.edu.cn020-61330051

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026